PointState Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

PointState Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-59,042	Closed	-$5.18M	–	126
2020 Q4	$5.18M	Sell	59,042 -249,109	-81%	-$19.7M	0.1%	92
2020 Q3	$23.4M	Buy	308,151 +57,981	+23%	+$5.87M	0.62%	37
2020 Q2	$30.9M	Buy	250,170 +56,793	+29%	+$5.64M	0.93%	22
2020 Q1	$16.3M	Sell	193,377 -258,863	-57%	-$22.3M	0.81%	21
2019 Q4	$38.2M	Buy	+452,240	New	+$34.2M	0.69%	41
2015 Q1	–	Sell	-275,000	Closed	-$24.9M	–	124
2014 Q4	$24.9M	Buy	+275,000	New	+$22.9M	0.42%	56

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital's BMRN Position: Q1 2021 in Review

PointState Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 59,042 shares — an estimated $5.18M sold.

PointState Capital first reported a position in BMRN in Q4 2014 and held it in 6 quarters. The position peaked at $38.2M in Q4 2019. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

PointState Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
PointState Capital sold 59,042 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $5.18M.
PointState Capital first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 6 quarters.
PointState Capital's BioMarin Pharmaceuticals position peaked at $38.2M in Q4 2019.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on PointState Capital's 13F filing for Q1 2021, filed 14 May 2021.